Last updated: March 4, 2026
What is NDC 16714-0534?
NDC 16714-0534 refers to the drug Ibrutinib (brand name Imbruvica). It is an oral Bruton’s tyrosine kinase (BTK) inhibitor used primarily for treating certain hematologic cancers such as mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström’s macroglobulinemia.
Market Overview
Market Size and Growth
The global oncology market was valued at approximately $168 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 9.2% through 2028. Ibrutinib accounts for significant revenue in this sector, particularly within B-cell malignancies.
Key drivers include:
- Increasing incidence of target cancers.
- Expansion of approved indications.
- Growing adoption of oral targeted therapies.
- Competitive landscape shifting with newer BTK inhibitors.
Competitive Landscape
Main competitors include:
- Acalabrutinib (Calquence) by AstraZeneca
- Zanubrutinib (Brukvec) by BeiGene
- Ongoing development of next-generation BTK inhibitors aiming for improved efficacy and safety profiles.
Market Penetration and Usage
Since FDA approval in 2013, Ibrutinib has seen steady market penetration. The medication is prescribed for:
- Chronic lymphocytic leukemia (CLL)
- Mantle cell lymphoma (MCL)
- Waldenström’s macroglobulinemia (WM)
In 2022, estimated global sales exceeded $6 billion, with the US accounting for over 80% of revenue.
Price Trends and Projections
Current Pricing Landscape
- U.S. wholesale acquisition cost (WAC): $13,000 to $15,000 per month per patient.
- Average annual cost: approximately $150,000.
- Price adjustments correlate with manufacturing costs, patent protections, and market competition.
Price Drivers
- Patent exclusivity: Patent for Ibrutinib extends until 2027 in the U.S.
- Biosimilar entry: Expected post-2027, which could reduce prices.
- Reimbursement policies: Managed care arrangements influence net prices.
Predictions for Future Pricing
- 2023–2025: Prices remain stable as patent exclusivity sustains market control.
- 2026–2027: Slight declines due to increased discounting and payer negotiations.
- Post-2027: Prices are projected to decline by 30-50%, assuming biosimilar competition takes hold.
Forecasted Market Impact on Price
| Year |
Estimated Average Price Per Year |
Key Factors |
| 2023 |
$14,000 |
Patent protection, high demand |
| 2024 |
$13,500 |
Price negotiations, market saturation |
| 2025 |
$13,000 |
Approaching patent expiry, biosimilar entry |
| 2026 |
$9,000–$10,000 |
Biosimilar approval, increased competition |
| 2027+ |
~$7,000–$8,000 |
Biosimilar market penetration, patent expiry |
Market Risks and Opportunities
Risks
- Patent expiry leading to biosimilar entry.
- Regulatory challenges or delays in approvals.
- Emerging therapies with better safety and efficacy profiles.
Opportunities
- Expansion into new indications.
- Development of combination therapies.
- Price reductions creating broader access.
Key Takeaways
- NDC 16714-0534 (Imbruvica) is a leading BTK inhibitor in hematologic malignancies.
- The U.S. market is dominant, with annual sales over $6 billion as of 2022.
- Price stability persists through 2025 owing to patent protection.
- Significant price reductions expected post-2027 with biosimilar competition.
- Market expansion hinges on new indications and combination treatments.
FAQs
1. When will biosimilars for Imbruvica enter the market?
Biosimilar approval is anticipated around 2027, following patent expiry.
2. How do patent expiration and biosimilar entry impact pricing?
Patent expiration allows biosimilar manufacturers to enter the market, typically reducing prices by 30-50%.
3. What are the main competitors for Imbruvica?
Acalabrutinib by AstraZeneca and Zanubrutinib by BeiGene.
4. What is the primary revenue driver for Imbruvica?
The treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
5. How might future regulatory developments affect Imbruvica?
New approvals for additional indications or modifications to existing patents could extend market exclusivity or influence pricing strategies.
References
[1] MarketWatch. (2023). Oncology drugs market size and forecasts.
[2] EvaluatePharma. (2022). Prescription sales and projections for BTK inhibitors.
[3] FDA. (2022). Approval history of Ibrutinib.
[4] IQVIA. (2022). U.S. prescription drug data.
[5] Biosimilar Development. (2023). Market entry timeline for BTK biosimilars.
